Abstract:Background: Cytokine fusion protein that modulates the immune response holds great potential for cancer immunotherapy. IL-2 is an effective treatment against advanced cancers. However, the therapeutic efficacy of IL-2 is limited by severe systemic toxicity. Several mutants recombinant IL-2 can increase antitumor activity and minimize systemic toxicity. Melittin is an attractive anticancer candidate because of its wide-spectrum lytic properties. We previously generated a bifunctional fusion protein melittin-MIL-2, composed of melittin and a mutant IL-2. The melittin-MIL-2 inhibited the growth of human ovarian cancer SKOV3 cells in vitro and in vivo tumor growth. However, whether this antitumor effect could also be used in cancer immunotherapy was unknown. To assess its cancer immunotherapy potential, we further investigated its more effective antitumor immune response and antitumor effect against cancers of different tissue origins in vitro and in vivo. Methods: The specific IL-2 activity of the melittin-MIL-2 fusion protein was tested on the cytokine growth dependent cell line CTLL-2. The cytolytic activity was detected by standard 4-h (51)Cr-release assays. PBMC stimulation in response to the melittin-MIL-2 was determined by IFN-γ release assay. We observed the cancer cell proliferation of different tissue origins by MTT assay. The ability of melittin-MIL-2 to inhibit tumor growth in vivo was evaluated by using human liver (SMMC-7721 cancer cells), lung (A549 cancer cells) and ovarian (SKOV3 cancer cells) cancer xenograft models. To assess the immunity within the tumor microenvironment, the level of some cytokines including IFN-γ, TNF-α, IL-12 and IL-4 was analyzed by ELISA. We injected the MDA-MB-231 cells and the melittin-MIL-2 into mice, and the anti-metastatic effect was examined by counting nodules in the lung. Results: The melittin-MIL-2 was more effective in inducing T cell and NK-cell cytotoxicity. The fusion protein significantly increased IFN-γ production in PBMCs. In vitro, the melittin-MIL-2 mediated immune cells killing or directly killed the cancer cell lines of different tissue origins. In vivo, the fusion protein exhibited stronger inhibition on the growth of transplanted human tumors compared to rIL-2. The melittin-MIL-2 treatment promoted the IFN-γ secretion in tumor tissues and decreased the immunosuppressive cells in vivo. Furthermore, the fusion protein reduced lung metastasis of breast cancer. Conclusions: This study provides the evidence that the melittin-MIL-2 can produce stronger immune stimulation and antitumor effects, and the fusion protein is a potent candidate for cancer immunotherapy.

Expression and Purification of Recombinant Atf-Mellitin, A New Type Fusion Protein Targeting Ovarian Cancer Cells, in P. Pastoris

Expression and Purification of the Melittin Gene from Polistes hebraeus by the GST Gene Fusion System

Expression of the Melittin Gene of Apis Cerana Cerana in Escherichia Coli

Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy

Construction of Membrane-lytic Immunotoxin by Melittin and Epidermal Growth Factor

[Construction, Expression and Purification of a Mammalian Secretory Recombinant Fusion Protein Rpc].

Inhibitory effect of recombinant adenovirus carrying melittin gene on hepatocellular carcinoma

Upregulation of EPSTI1/Drp1/AKT1 Signaling Pathways Using pDNA/Melittin Against Breast Cancer

Expression of tumor necrosis factor receptor-immunoglobulin G1 Fc fusion protein in glycoengineered Pichia pastoris

The Construction of Anti-EGFR Single Chain Variable Fragment Fused with Gelonin Toxin Prokaryotic Expressing Plasmid and the Study of Its Anti-tumor Effects

Construction and Characterization of the Recombinant Immunotoxin RTA-4D5-KDEL Targeting HER2/neu-positive Cancer Cells and Locating the Endoplasmic Reticulum.

TAT-RhoGDI2, a Novel Tumor Metastasis Suppressor Fusion Protein: Expression, Purification and Functional Evaluation.

High Level Expression and Characterization of the Recombinant Immunotoxin DAB389-4D5 Scfv Targeting HER2/neu-positive Ovarian Carcinoma Cells

Melittin-encapsulating Peptide Hydrogels for Enhanced Delivery of Impermeable Anticancer Peptides.

Specific Inhibition of Hepatocarcinoma Cells by Recombinant Adenovirus Expressing Melittin

THE STUDY OF EXPRESSION AND FUNCTION OF ANTIBODY-CYTOKINE FUSION PROTEIN 183B2scfv-Interleukin 2

Selection and Characterization of Human Anti-MAGE-A1 Scfv and Immunotoxin

Selective Cytotoxicity to HER2-Positive Tumor Cells by a Recombinant E23sfv-Td-tbid Protein Containing a Furin Cleavage Sequence

Fusion Expressing of Melitin and Thanantin Heteropeptide(MT) in E.coli

Recombinant Expression and Purification of a MAP30-cell Penetrating Peptide Fusion Protein with Higher Anti-Tumor Bioactivity.

Selective Inhibition of Cancer Cells by Enzyme-Induced Gain of Function of Phosphorylated Melittin Analogues.